• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Acute Coronary Syndromes - Pipeline Review, Q1 2011 - Product Image

Acute Coronary Syndromes - Pipeline Review, Q1 2011

  • ID: 1574070
  • February 2011
  • 62 pages
  • Global Markets Direct

Acute Coronary Syndromes - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Acute Coronary Syndromes - Pipeline Review, Q1 2011', provides an overview of the Acute Coronary Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Acute Coronary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome. 'Acute Coronary Syndromes - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Coronary Syndrome.
- A review of the Acute Coronary Syndrome products under development READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Coronary Syndromes Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Coronary Syndromes
Acute Coronary Syndromes Therapeutics under Development by Companies
Acute Coronary Syndromes Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Acute Coronary Syndromes Therapeutics Development
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Merck & Co., Inc.
Ablynx
Astellas Pharma Inc.
Eisai Co., Ltd.
Glenmark Pharmaceuticals Ltd.
Bayer AG
Momenta Pharmaceuticals, Inc.
CSL Limited
BioInvent International AB
Resverlogix Corp.
Viron Therapeutics, Inc.
Regado Biosciences.
Cerenis Therapeutics SA
VIA Pharmaceuticals, Inc.
Anthera Pharmaceuticals‚ Inc.
Athera Biotechnologies AB
The Medicines Company (Leipzig) GmbH
Universities/Institutes Involved in Acute Coronary Syndromes Therapeutics Development
Acute Coronary Syndromes - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
A-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
A-002 + Lipitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Angiomax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspirin I.V. - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brilinta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cangrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Darapladib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Efient - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Otamixaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vorapaxar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Xarelto - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Adenocor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clopidogrel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Coenzyme Q10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GIK + Intensive Insulin Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Niaspan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Red Blood Cell Transfusion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Acute Coronary Syndromes - Featured News
1. Dec 17, 2010: AstraZeneca Receives Complete Response Letter From FDA For BRILINTA
2. Dec 16, 2010: Viron Announces Publication Of VT-111 Phase IIa Data In Cardiovascular Journal
3. Dec 06, 2010: AstraZeneca Receives European Approval For Brilique For Treatment Of Acute Coronary Syndromes
4. Nov 18, 2010: Bristol-Myers Squibb Company And Pfizer Discontinue Phase III APPRAISE-2 Study With Apixaban In Acute Coronary Syndrome
5. Nov 18, 2010: NicOx Presents NCX 6560 Phase Ib Results At AHA 2010 Scientific Sessions
6. Nov 10, 2010: BioInvent Receives Approval To Start Phase II Trial For Cardiovascular Drug BI-204
7. Oct 26, 2010: Takeda Announces Top Line Results From Phase II Study Of Investigational Compound, TAK-442 For Patients With ACS
8. Oct 26, 2010: Takeda Announces Top Line Results From Phase II Study Of TAK-442 For Treatment Of Acute Coronary Syndrome
9. Oct 01, 2010: AstraZeneca Announced The Initiation Of A Large, International, Clinical Outcomes Study For The Investigational Oral Antiplatelet, Ticagrelor (BRILINTA/BRILIQUE)
10. Sep 24, 2010: AstraZeneca Receives CHMP Positive Opinion For BRILIQUE For Treatment Of Acute Coronary Syndromes
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Coronary Syndromes, 2011
Products under Development for Acute Coronary Syndromes – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Sanofi-Aventis, 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
GlaxoSmithKline plc, 2011
Merck & Co., Inc., 2011
Ablynx, 2011
Astellas Pharma Inc., 2011
Eisai Co., Ltd., 2011
Glenmark Pharmaceuticals Ltd., 2011
Bayer AG, 2011
Momenta Pharmaceuticals, Inc., 2011
CSL Limited, 2011
BioInvent International AB, 2011
Resverlogix Corp., 2011
Viron Therapeutics, Inc., 2011
Regado Biosciences., 2011
Cerenis Therapeutics SA, 2011
VIA Pharmaceuticals, Inc., 2011
Anthera Pharmaceuticals‚ Inc., 2011
Athera Biotechnologies AB, 2011
The Medicines Company (Leipzig) GmbH, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Acute Coronary Syndromes, 2011
Products under Development for Acute Coronary Syndromes – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos